OGN - EMA panel recommends extending indication for Organon's fertility treatment Elonva

The European Union drug regulator's Committee for Medicinal Products for Human Use recommended extending the indication for Organon's (NYSE:OGN) fertility treatment, Elonva.  The drug regulator said Elonva is indicated for the treatment of adolescent males, that are 14 years and older, with hypogonadotropic hypogonadism, in combination with human Chorionic Gonadotropin. Elonva was approved as a hormonal medicine used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries. It is used together with a gonadotrophin-releasing hormone (GnRH) antagonist. The drug was approved by the European Commission in January 2010.

For further details see:

EMA panel recommends extending indication for Organon's fertility treatment Elonva